

Programme

Sunday August 31, 2025

15:30 **Registration**

17:30 **Opening Ceremony**

17:45 **Supramolecular Peptide Therapeutics: A New Frontier for Regeneration (IL01)**

Prof. Samuel STUPP
(NORTHWESTERN UNIVERSITY, Evanston, IL, United States)

18:30 **Welcome Reception**

Programme

Monday September 1, 2025

- 08:00 Registration**
- 08:30 Peptide Catalysis – From Simple to Complex Environments (IL02)**
Prof. Helma WENNEMERS
(ETH ZURICH, Zürich, Switzerland)
- 09:15 AZD2389, a First in Class Small Molecule Inhibitor of Fibroblast Activation Protein (FAP) (IL03)**
Dr Anneli NORDQVIST
(ASTRAZENECA, BIOPHARMACEUTICALS R&D, Gothenburg, Sweden)
- 10:00 Advancing Medicinal Chemistry: Harnessing Photochemical and Electrochemical Technologies for Synthesis and Functionalization (OC01)**
Dr Sven RUF
(SANOFI, Frankfurt am Main, Germany)
- 10:15 Coffee-break and Exhibition**
- 10:45 The Synergy of Light, Organocatalysis, and Enzymes: New Radical Opportunities (IL04)**
Prof. Paolo MELCHIORRE
(UNIVERSITY OF BOLOGNA, Bologna, Italy)
- 11:30 Therapeutic Opportunities within the Ubiquitin System (IL05)**
Dr Malte GERSCH
(TU DORTMUND, Dortmund, Germany)
- 12:15 Discovery of AZD6793, a Highly Potent and Selective IRAK4 Inhibitor in Clinical Development For The Treatment of COPD (OC02)**
Dr Ina TERSTIEGE
(ASTRAZENECA, Mölndal, Sweden)
- 12:30 Lunch and Exhibition**
- 14:00 HTE OS: Attaching Wings to Chemistry (IL06)**
Dr Georg WUITSCHIK (F. HOFFMANN-LA ROCHE, Basel, Switzerland)
Dr Vera JOST (F.HOFFMANN-LA ROCHE, Basel, Switzerland)
- 14:45 Specificity Requires Size: From Small Peptides to Large Proteins to Gigantic Bioconjugates for Targeted Therapy (IL07)**
Prof. Annemieke MADDER
(UGENT, Ghent, Belgium)
- 15:30 Coffee-break and Exhibition**
- 16:00 Selective Reduction of Esters to Aldehydes Using Fiddler Crab-Type Boranes (OC03)**
Mr Ádám DUDÁS
(HUN-REN RESEARCH CENTRE FOR NATURAL SCIENCES, Budapest, Hungary)
- 16:15 Future-proofing Synthesis at AstraZeneca: Sustainability, Green Chemistry and Project Delivery (IL08)**
Dr Gail WRIGLEY
(ASTRAZENECA, Cambridge, United Kingdom)

Programme

- 17:00 Synthesis in a Boron World (IL09)**
Prof. Varinder K. AGGARWAL
(UNIVERSITY OF BRISTOL, Bristol, United Kingdom)
- 17:45 End of the day**

Programme

Tuesday September 2, 2025

- 08:30 On the Clinical Relevance of Photopharmacology (IL10)**
Prof. Dirk TRAUNER
(UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA, United States)
- 09:15 CK-4021586: A Novel Cardiac Myosin Inhibitor with an Alternative Mechanism of Action for the Treatment of HFpEF (IL11)**
Dr Luke ASHCRAFT
(CYTOKINETICS, San Francisco, United States)
- 10:00 Conformationally Locked Glycosidase Inhibitors, Probes and Degraders: Bridging Chemical Biology and Therapeutic Advances (OC04)**
Dr Marta ARTOLA
(LEIDEN UNIVERSITY, Leiden, The Netherlands)
- 10:15 Coffee break and Exhibition**
- 10:45 Recent Developments in Carbon Isotope Labeling (IL12)**
Dr Davide AUDISIO
(CEA-SACLAY, Gif-sur-Yvette, France)
- 11:30 Design and Synthesis of the WRN Inhibitor HRO761 (IL13)**
Dr Jürgen HINRICHS
(NOVARTIS, Basel, Switzerland)
- 12:15 PRIZE winner EFMC-YMCS 2024 (OC05)**
Development of Clinically-Used HIF-1 ? PHD Inhibitors into Potent and Selective ?-Butyrobetaine Hydroxylase Inhibitors
Mr Thomas CORNER
(YALE UNIVERSITY, New Haven, United States)
- 12:30 Lunch and Exhibition**
- 13:30 Poster Session 1**
- 14:30 Discovery and Development of PXG-CycK, a Highly Potent, Selective, and Orally Available Cyclin K Molecular Glue Degradar for the Treatment of Solid Tumours (IL14)**
Dr Francis FORSTER
(PROXYGEN, Vienna, Austria)
- 15:15 Discovery of BMS-986470, a First-in-class Molecular Glue Dual Degradar of Zinc Finger and BTB Domain Containing 7A (ZBTB7A) and Widely Interspaced Zinc Finger Protein (WIZ) for the Treatment Sickle Cell Disease (IL15)**
Dr Thomas CUMMINS
(BRISTOL MYERS SQUIBB, San Diego, CA, United States)
- 16:00 Design of Fluorescent Organic Nanoparticles for Highly Performant Multiplexed Immunoassays (OC06)**
Dr Emanuela BERRINO
(CEA PARIS SACLAY, Gif-sur-Yvette, France)
- 16:15 Coffee break and Exhibition**

Programme

- 16:45** **Discovery of Glovadalen (UCB0022), an Oral, Brain Penetrant Positive Allosteric Modulator of the Dopamine D1 Receptor (D1 PAM) Currently in Phase 2 Clinical Trials (IL16)**
Dr Anne VALADE
(UCB, Braine-l'Alleud, Belgium)
- 17:30** **Chemical Tailoring at C—H Bonds (IL17)**
Prof. M. Christina WHITE
(UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN, Urbana, United States)
- 18:15** **End of the day**

Programme

Wednesday September 3, 2025

- 08:30 Therapeutic Splice Modifiers: Embracing the Road Less Traveled (IL18)**
Dr Matthew WOLL
(PTC THERAPEUTICS, South Plainfield, NJ, United States)
- 09:15 Molecular Complexity from Simple Building Blocks: Asymmetric C-H Activation or Rare Hypervalent Compounds? (IL19)**
Prof. Joanna WENCEL-DELORD
(UNIVERSITY OF WÜRZBURG, Würzburg, Germany)
- 10:00 High-Throughput Structure Guided Design Enables Binding Site Mapping and Rapid Fragment Expansion on 'Undruggable' E3 Ligase SOCS2 (OC07)**
Dr Roberta IBBA
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)
- 10:15 Coffee Break and Exhibition**
- 10:45 Methods and Strategies for Tackling Assay Interference Caused by Small Molecules (IL20)**
Prof. Johannes KIRCHMAIR
(UNIVERSITY OF VIENNA, Vienna, Austria)
- 11:30 Fragment-Based Discovery of Allosteric Modulators of α -Glucocerebrosidase (GCase) (IL21)**
Dr Nick PALMER
(ASTEX PHARMACEUTICALS, Cambridge , United Kingdom)
- 12:15 Synthesis of Four-Membered Heterocycles via Olefin-Thianthreneation (OC08)**
Mr András KOTSCHY
(RESEARCH CENTRE FOR NATURAL SCIENCES, Budapest, Hungary)
- 12:30 Lunch and Exhibition**
- 13:30 Poster Session 2**
- 14:30 Cryo-EM Enables Structure-Based Drug Design for Membrane Protein Targets at Boehringer Ingelheim (IL22)**
Dr Rebecca EBENHOCH
(BOEHRINGER INGELHEIM, Biberach, Germany)
- 15:15 Discovery and First-Time-Disclosure of BI 1291583: a DPP1 Inhibitor Clinical Candidate for the Treatment of Bronchiectasis (OC09)**
Dr Marc GRUNDL
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach, Germany)
- 15:45 EFMC Prizes Session - Ceremony & Lectures**
- 15:50 EFMC Prize for a Young Medicinal Chemist or Chemical Biologist in Academia Mining Microbial Genomes for Novel Anti-cancer Antibiotics and Biosynthetic Pathways (PR01)**
Dr Joleen MASSCHELEIN
(KU LEUVEN, Leuven, Belgium)
- 16:05 EFMC Prize for a Young Medicinal Chemist or Chemical Biologist in Industry Targeting the SHOC2-RAS Interaction in RAS-Mutant Cancers (PR02)**

Programme

Dr Veronika EHMKE
(NOVARTIS BIOMEDICAL RESEARCH, Basel, Switzerland)

16:20 Coffee Break and Exhibition

16:50 Break-it-to-Make-it Strategies for Chemical Synthesis Inspired by Complex Natural Products (IL23)
Prof. Richmond SARPONG
(UNIVERSITY OF CALIFORNIA, Berkeley, United States)

17:20 End of the day

20:00 Conference Dinner

Programme

Thursday September 4, 2025

- 08:30** **Flow Automation for Drug Discovery Expanding the Limits of Accessible Chemical Space (IL24)**
Dr Jesus ALCAZAR
(JOHNSON & JOHNSON INNOVATIVE MEDICINE, Toledo, Spain)
- 09:15** **Two Nobel-prized Chemistries Combined Towards New Topical Treatments for Non-Healing Wounds (IL25)**
Prof. Paula GOMES
(UNIVERSITY OF PORTO, Porto, Portugal)
- 10:00** **First in Class Antiviral Agents Targeting the Helicase Nonstructural Protein of Pandemic Potential Coronaviruses and Flaviviruses (OC10)**
Prof. Thomas BANNISTER
(WERTHEIM UF SCRIPPS INSTITUTE, Jupiter, United States)
- 10:15** **Coffee break and Exhibition**
- 10:45** **Discovery and in vivo Efficacy of Novel Aminopeptidase Modulators (IL26)**
Dr Christopher TINWORTH
(GLAXOSMITHKLINE, Stevenage, United Kingdom)
- 11:30** **Boronic Acids a Useful Construction Tool for Chemical Biology (IL27)**
Dr Pedro GOIS
(UNIVERSITY OF LISBON, Lisboa, Portugal)
- 12:15** **Closing Remarks & Prizes ceremony**
- 12:30** **End of the Symposium**